Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Finished Goods (2016 - 2020)

Historic Finished Goods for United Therapeutics (UTHR) over the last 11 years, with Q1 2020 value amounting to $43.8 million.

  • United Therapeutics' Finished Goods fell 798.32% to $43.8 million in Q1 2020 from the same period last year, while for Mar 2020 it was $43.8 million, marking a year-over-year decrease of 798.32%. This contributed to the annual value of $43.2 million for FY2019, which is 1129.36% down from last year.
  • As of Q1 2020, United Therapeutics' Finished Goods stood at $43.8 million, which was down 798.32% from $43.2 million recorded in Q4 2019.
  • In the past 5 years, United Therapeutics' Finished Goods ranged from a high of $62.2 million in Q3 2017 and a low of $37.3 million during Q2 2016
  • For the 5-year period, United Therapeutics' Finished Goods averaged around $48.9 million, with its median value being $48.7 million (2018).
  • As far as peak fluctuations go, United Therapeutics' Finished Goods surged by 6514.75% in 2017, and later crashed by 2057.88% in 2018.
  • Quarter analysis of 5 years shows United Therapeutics' Finished Goods stood at $49.7 million in 2016, then rose by 12.47% to $55.9 million in 2017, then fell by 12.88% to $48.7 million in 2018, then fell by 11.29% to $43.2 million in 2019, then increased by 1.39% to $43.8 million in 2020.
  • Its last three reported values are $43.8 million in Q1 2020, $43.2 million for Q4 2019, and $45.0 million during Q3 2019.